Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study.
Quaglino P, Marenco F, Osella-Abate S, Cappello N, Ortoncelli M, Salomone B, Fierro MT, Savoia P, Bernengo MG. Quaglino P, et al. Among authors: ortoncelli m. Ann Oncol. 2010 Feb;21(2):409-414. doi: 10.1093/annonc/mdp325. Epub 2009 Jul 21. Ann Oncol. 2010. PMID: 19622589 Free article.
Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.
Chiricozzi A, Ortoncelli M, Schena D, Gori N, Ferrucci SM, Babino G, Napolitano M, Fargnoli MC, Stingeni L, Rossi M, Romanelli M, Balestri R, Pellegrino M, Parodi A, Bertoldi AM, Palazzo G, Antonelli F, Pitino A, Tripepi G, Fabbrocini G, Balato A, Marzano AV, Girolomoni G, Ribero S, Peris K. Chiricozzi A, et al. Among authors: ortoncelli m. Am J Clin Dermatol. 2023 Nov;24(6):953-961. doi: 10.1007/s40257-023-00798-0. Epub 2023 Jun 15. Am J Clin Dermatol. 2023. PMID: 37322324 Free PMC article.
Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.
Chiricozzi A, Ortoncelli M, Schena D, Gori N, Ferrucci SM, Babino G, Napolitano M, Fargnoli MC, Stingeni L, Rossi M, Romanelli M, Balestri R, Pellegrino M, Parodi A, Bertoldi AM, Palazzo G, Antonelli F, Pitino A, Tripepi G, Fabbrocini G, Balato A, Marzano AV, Girolomoni G, Ribero S, Peris K. Chiricozzi A, et al. Among authors: ortoncelli m. Am J Clin Dermatol. 2023 Nov;24(6):963-964. doi: 10.1007/s40257-023-00813-4. Epub 2023 Aug 19. Am J Clin Dermatol. 2023. PMID: 37597128 Free PMC article. No abstract available.
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series.
Gori N, Ippoliti E, Ferrucci SM, Balato A, Ortoncelli M, Maurelli M, Galluzzo M, Munera Campos M, Seremet T, Di Nardo L, Antonelli F, Coscarella G, Conrad C, Carrascosa JM, Bianchi L, Argenziano G, Ribero S, Girolomoni G, Marzano AV, Chiricozzi A, Peris K; MEDaCoTRA Study Group. Gori N, et al. Among authors: ortoncelli m. J Eur Acad Dermatol Venereol. 2024 Feb 29. doi: 10.1111/jdv.19929. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38421043 No abstract available.
97 results